prednisone / administration & dosage

Explore academic connections and research related to this keyword

178
Views
4
Total Connections
Search More Keywords

Related Articles & Bibliographies

1
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study
Chiappella A;Martelli M;Angelucci E;Brusamolino E;Evangelista A;Carella AM;Stelitano C;Rossi G;Balza...
2017 the lancet oncology 403 views
2
Self-management plans in the primary care of patients with chronic obstructive pulmonary disease
McGeoch GR;Willsman KJ;Dowson CA;Town GI;Frampton CM;McCartin FJ;Cook JM;Epton MJ;;
2006 Respirology (Carlton, Vic.) 264 views
3
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial
Palumbo A;Bringhen S;Caravita T;Merla E;Capparella V;Callea V;Cangialosi C;Grasso M;Rossini F;Galli...
2006 Lancet (London, England) 240 views
4
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
Cavo M;Gay F;Beksac M;Pantani L;Petrucci MT;Dimopoulos MA;Dozza L;van der Holt B;Zweegman S;Oliva S;...
2020 The Lancet. Haematology 330 views

Related Journals

No Journals Found

No journals are currently associated with this keyword.

Related Research Groups

No Research Groups Found

No research groups are currently associated with this keyword.

Explore Related Keywords

transplantation National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't adult female male middle aged Comparative Study risk factors Clinical Trial Phase III